Guardant Health, Inc. (NASDAQ:GH – Get Ratings) – Analysts at SVB Leerink lowered their fiscal 2022 earnings estimates for shares of Guardant Health in a report released on Thursday, Jan. 12. SVB analyst Leerink P. Souda now expects the company to post earnings of ($6.59) per share for the year, down from its previous estimate of ($6.57). The consensus estimate for Guardant Health’s current full-year earnings is ($6.46) per share. SVB Leerink also released estimates for Guardant Health’s fourth quarter 2022 earnings at ($1.55) EPS, first quarter 2023 earnings at ($1.39) EPS, second quarter 2023 earnings at ($1 .31) EPS, FY2023 earnings at ($5.20) EPS and FY2024 earnings at ($4.84) EPS.
Guardant Health (NASDAQ:GH – Get Rating) last announced its earnings results on Thursday, Nov. 3. The company reported ($1.58) EPS for the quarter, missing the ($1.27) consensus estimate by ($0.31). Guardant Health had a negative return on equity of 145.58% and a negative net margin of 140.58%. The company reported revenue of $117.40 million for the quarter, compared to the consensus estimate of $118.18 million.
Several other stock analysts have also rated GH. Cowen reduced his price target on Guardant Health stock from $110.00 to $83.00 in a research report on Friday, Nov. 4. In a research report on Friday, December 16, BTIG Research reduced its price target on Guardant Health shares from $80.00 to $60.00. JPMorgan Chase & Co. reduced its price target on Guardant Health from $100.00 to $85.00 and set an “overweight” valuation for the company in a research report on Friday, Nov. 18. Stephens cut his price target on Guardant Health from $99.00 to $90.00 and set an “overweight” rating on the stock in a report on Monday, Nov. 7. Finally, Cowen reduced the target price on Guardant Health from $83.00 to $70.00 in a report on Friday, December 16. One analyst has rated the stock with a hold rating, and fifteen have issued a buy rating on the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $90.39.
Guardant health trading down 0.8%
Shares of GH opened at $30.43 on Monday. The stock has a 50-day simple moving average of $39.99 and a 200-day simple moving average of $46.95. The stock has a market cap of $3.12 billion, a P/E ratio of -5.13, and a beta of 0.83. Guardant Health has a fifty-two week low of $24.63 and a fifty-two week high of $79.24. The company has a quick ratio of 6.10, a current ratio of 6.46, and a debt-to-equity ratio of 6.82.
Insider buying and selling
In other Guardant Health news, insider Kumud Kalia sold 3,125 shares of the company in a deal that took place on Tuesday, Nov. 15. The shares sold at an average price of $51.87, for a total value of $162,093.75. As a result of the transaction, the insider now owns 20,135 shares of the company, valued at approximately $1,044,402.45. The transaction was disclosed in a filing with the SEC, which can be accessed via this link. 5.90% of the shares are currently owned by corporate insiders.
Institutional income and expenses
A number of institutional investors and hedge funds have recently bought and sold shares in GH. Xponance Inc. increased its position in Guardant Health by 2.4% in the third quarter. Xponance Inc. now owns 11,639 shares of the company worth $627,000 after acquiring another 269 shares in the recent quarter. Captrust Financial Advisors increased its stake in Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company valued at $44,000 after buying another 271 shares in the recent quarter. Commonwealth Equity Services LLC increased its position in Guardant Health stock by 4.9% in the second quarter. Commonwealth Equity Services LLC now owns 6,120 shares of the company valued at $246,000 after purchasing an additional 286 shares during the most recent quarter. Manchester Capital Management LLC increased its stake in Guardant Health shares by 43.0% during the third quarter. Manchester Capital Management LLC now owns 965 shares of the company worth $52,000 after acquiring an additional 290 shares in the recent quarter. Finally, Baird Financial Group Inc. increased its stakes in Guardant Health stock by 2.1% during the third quarter. Baird Financial Group Inc. now owns 14,580 shares of the company valued at $785,000 after acquiring another 296 shares during the most recent quarter. Hedge funds and other institutional investors own 90.43% of the company’s shares.
Guardant Health Company Profile
(Get Rating)
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analyzes in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer; and GuardantINFORM, an in-silico research platform comprising a clinical-genomic liquid biopsy dataset of patients with advanced cancer.
See also
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Guardant Health, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are whispering to their customers to buy now before the broader market catches on…and Guardant Health wasn’t on the list.
While Guardant Health currently has a “Moderate Buy” rating among analysts, senior analysts believe these five stocks are better buys.
View the five titles here
